Skip to main content
. Author manuscript; available in PMC: 2021 Jul 6.
Published in final edited form as: Med Care. 2020 Jun;58(Suppl 6 1):S40–S45. doi: 10.1097/MLR.0000000000001318

Table 3.

Change in predicted utilization and expenditures (amount as modeled in the post period vs. amount as expected had the pre period trend continued) for Treatment (ACC assignees) vs. Comparator (other large practice assignees), 18 months after ACC activation

Treatment Predictions Comparator Predictions Difference at 18 months: Treatment vs. Comparator, Post vs. Pre

A B C D Difference = (A-B) - (C-D)

Enrollment Predicted Outcome Under Post Trend Under Pre Trend Under Post Trend Under Pre Trend Difference 95% Confidence Interval P-Value
TANF Plan Expenditures $393.76 $389.69 $386.97 $423.65 $40.74 (−$75.99, $157.48) 0.492
Any Hospitalization 1.49% 1.25% 1.45% 1.50% 0.29% (−0.23%, 0.81%) 0.278
Any ED Visit 8.85% 8.07% 8.29% 8.29% 0.79% (−0.32%, 1.89%) 0.162
SSI (Without Medicare) Plan Expenditures $852.01 $972.92 $800.77 $870.81 −$50.87 (−$202.09, $100.36) 0.508
Any Hospitalization 4.01% 4.13% 3.72% 3.77% −0.07% (−0.92%, 0.77%) 0.862
Any ED Visit 12.47% 11.79% 10.95% 10.99% 0.72% (−0.46%, 1.90%) 0.233
Expansion Plan Expenditures $511.62 $243.02 $469.07 $573.49 $373.02 ($−100.26, $846.30) 0.121
Any Hospitalization 1.66% 1.71% 1.37% 1.01% −0.41% (−2.64%, 1.83%) 0.723
Any ED Visit 7.56% 8.21% 6.79% 10.82% 3.37% (−1.89%, 8.64%) 0.209
UHC Medicare-Medicaid Dual Plan Expenditures $416.19 $403.27 $446.12 $499.16 $65.96 (−$121.81, $253.73) 0.488
Any Hospitalization 1.49% 1.26% 1.71% 2.00% 0.52% (−0.53%, 1.58%) 0.332
Any ED Visit 4.16% 4.45% 4.17% 3.90% −0.55% (−2.38%, 1.27%) 0.551

Notes: Predictions made using interrupted time series segmented regression analysis. Change in outcome at 18 months estimated by comparing (1) the 18-month outcome amount in the post period with (2) what the outcome amount would have been at 18 months after ACC activation (real or proxy) if pre period trends had continued. Linear regression used for expenditures; logistic regression used for utilization outcomes. Sample is person-months from 2010–2016.

*

denotes significance at p < .05. Regression covariates of interest were study Group (treatment [ACC assignees] vs. comparator [other large practice assignees]); a linear monthly time trend counting months before and after ACC activation (real or proxy; ACC activation defined as time zero), indicators and splines for the post period (months 0 and after); and the interactions between these variables and Group. Other covariates included sex, age group, race, language, 17 comorbidity indicators arthritis, asthma, atrial fibrillation, autism, cancer, chronic obstructive pulmonary disease, congestive heart failure, dementia, depression, HIV, hyperlipidemia, liver disease, myocardial infarction, osteoporosis, schizophrenia, stroke, and substance abuse), state-by-year fixed effects, an indicator for whether a state had adopted the Medicaid Expansion in the given month, and seasonality. Repeated measures adjusted for using generalized estimating equations (GEE), clustering by practice.